A screening method

Through the combination of fluorescent molecular labeling technology, high-connotation cell imager and flow cytometer, high-throughput automated screening of monoclonal antibodies is achieved, solving the problems of low efficiency and difficulty in automation in the existing technology, and improving the antibody screening Efficiency and accuracy.

CN114441752BActive Publication Date: 2024-11-26SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202011211640.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-11-03
Publication Date
2024-11-26
Estimated Expiration
2040-11-03

AI Technical Summary

Technical Problem

The existing monoclonal antibody screening methods are inefficient, unable to meet the needs of high-throughput screening, and difficult to automate, resulting in a lot of manual operations, time-consuming, and inability to ensure monoclonality, affecting the efficiency and accuracy of antibody discovery.

Method used

Using fluorescent molecular labeling technology combined with high-connotation cell imager and flow cytometer, cells secreting target antibodies are automatically screened by excitating fluorescent molecules of different wavelengths, and the target cells are distinguished by photoactivation and photoconversion characteristics to achieve high-throughput antibody screening. .

Benefits of technology

It improves the efficiency and accuracy of antibody screening, realizes high-throughput automated screening, and provides sufficient number of cell samples for subsequent amplification and screening, which helps to discover antibodies with high affinity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114441752B_ABST
    Figure CN114441752B_ABST
Patent Text Reader

Abstract

The present invention discloses a screening method, and relates to the field of biotechnology. The screening method of the present invention is to mix and incubate candidate cells labeled with a first fluorescent molecule, a capture antigen, and a labeled antibody against a target antibody, and then use a high-content cell imager to label and flow cytometer to sort, so as to screen out cells that secrete the target antibody. The screening method disclosed in the present invention can complete the labeling and sorting of target candidate cells in a high-throughput and automated manner by labeling with fluorescent molecules and combining a high-content cell imager and a flow cytometer, and provide a sufficient number of cell bases for subsequent amplification of its antibody sequence and screening of antibodies with affinity, and the method greatly improves the screening efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to a screening method. Background Art

[0002] Since Kohler and Milstein established hybridoma technology in 1975, thousands of different monoclonal antibodies have been produced. Some of them are used for scientific research, some are used for clinical diagnosis, and some are used to treat various diseases, such as tumors, immune system diseases, cardiovascular and cerebrovascular diseases, etc. Monoclonal antibodies have extremely high commercial value. Among the top ten best-selling drugs in 2019, therapeutic monoclonal antibodies contributed 73% of the total sales, reaching US$87 billion. It is estimated that by 2025, the global therapeutic monoclonal antibody market will reach US$300 billion. For a drug target, many antibodies need to be screened before it is possible to select a candidate antibody drug that can be used in clinical research, so an efficient and reliable antibody discovery platform is essential.

[0003] So far, the main monoclonal antibody discovery technologies are divided into hybridoma technology, surface display technology and single B cell technology.

[0004] Hybridoma technology is developed from cell fusion technology. Splenic B lymphocytes and myeloma cells are fused to form B lymphocyte-myeloma cell hybrids. Only this hybrid can proliferate and survive indefinitely in HAT culture medium and secrete antibodies. Although this technology can screen specific antibodies, the disadvantages of this method are also obvious:

[0005] (1): Manual operation is required, and there are too many steps to operate and repeat;

[0006] (2): Slow speed and low efficiency, which cannot meet the requirements for high-throughput screening;

[0007] (3): Monoclonality cannot be guaranteed and 3-4 subclonings are required, which is labor-intensive and time-consuming;

[0008] (4): Before limiting dilution ELISA testing, it is not known which clone meets the antigen specificity requirements.

[0009] Therefore, all clones need to be identified by ELISA at least once. After 45 years of development, some equipment that can reduce the manual operation of hybridoma screening has been produced, such as the ClonePix system. This system uses a semi-solid culture method to grow cells into single, independent and dispersed monoclones on the culture medium. Fluorescent-labeled clone detection reagents are added to the semi-solid culture medium. As the clone growth time increases, more fluorescent protein complexes will gather around the clone, and then the clones to be selected will be picked out one by one by picking the head. Although this technology reduces the manual operation of hybridoma screening, it also has some disadvantages. For example, first of all, hybridomas must be able to grow well on semi-solid culture medium, so it is necessary to develop a suitable culture medium. Secondly, the size and density of the clone have a great influence on the accuracy of automated clone picking. If the clone is too small, it will affect identification and picking. If the clone is too dense, it is easy to affect the monoclonality of the clone picked. Finally, the robotic arm has high requirements for selection accuracy, so the equipment needs to be carefully maintained on a daily basis.

[0010] Another major method for antibody discovery is surface display technology. The most widely used are phage display and yeast display technology. The principle is to amplify the antibody heavy chain variable region (VH) and light chain variable region (VL) of B lymphocytes by PCR, insert the amplified fragments into the vector, and express the antibody molecule as a Fab fragment or a single-chain antibody (scFv) fused with a single-chain phage coat protein or a protein on the surface of yeast, so as to display the antibody on the surface of phage or yeast. The method of antigen screening can obtain monoclonal antibodies specific to the target antigen after affinity adsorption-elution-amplification and other steps. However, the heavy antibody chain and light antibody chain of the variable region in this method are randomly combined, which makes a large part of the pairing meaningless. Moreover, most antibodies screened from these display libraries need to be further matured to meet affinity requirements.

[0011] Single B cell technology has been developed in recent years. This technology can directly separate and express antibodies from single B lymphocytes of mammals or humans, which can save a lot of screening time. At present, the main single B cell technology targets memory B cells, because the cell surface expresses corresponding IgG, which can be sorted (flow sorting, magnetic sorting, or microfluidic sorting) after coupling with labeled antigens (fluorescent or magnetic), thereby achieving high-throughput screening. Lotta von Boehmer et al. sorted memory B cells that can bind to antigens into 96-well PCR plates through flow sorting, amplified the variable regions of heavy and light chains, and then expressed and screened specific antibodies. However, this type of method can only target memory B cells that express IgG on the cell surface. The antibodies expressed by plasma cells are in secretory form, so they cannot be detected by this method. Alison M Clargo et al. established an in situ fluorescence method (fluorescent foci method), and took out the cells that secreted specific antibodies through micromanipulation methods, and then amplified the variable regions of heavy and light chains and expressed antibodies. However, this method requires micromanipulation to remove the target cells, which is time-consuming and labor-intensive and cannot be performed at a high throughput.

[0012] In view of this, the present invention is proposed. Summary of the invention

[0013] The object of the present invention is to provide a screening method. More specifically, the present invention provides a screening method for antibodies and their secretory cells.

[0014] The present invention is achieved in that:

[0015] In one aspect, the present invention provides a method for screening cells that secrete a target antibody, comprising the following steps:

[0016] Step (a): labeling the candidate cells with a first fluorescent molecule;

[0017] Step (b): adding the candidate cells labeled with the first fluorescent molecule and the labeled antibody against the target antibody to a container fixed with a capture antigen, mixing and incubating to obtain a cell fluid; wherein the capture antigen can specifically bind to the target antibody; and the labeled antibody is labeled with a second fluorescent molecule;

[0018] The first fluorescent molecule has the following properties: the fluorescence emitted by the first fluorescent molecule after being excited by the first excitation light is different from the fluorescence emitted by the second fluorescent molecule after being excited by the first excitation light; the first fluorescent molecule is in a photoactivated or photoconverted state after being excited by the second excitation light, and emits the first fluorescence after being excited by the third excitation light in the photoactivated or photoconverted state; and the first fluorescent molecule emits the second fluorescence after being directly excited by the third excitation light without being excited by the second excitation light; the wavelength of the first fluorescence is different from the wavelength of the second fluorescence, or the wavelength of the first fluorescence is the same as the wavelength of the second fluorescence but the fluorescence intensity is different; wherein the wavelength of the first excitation light is different from the wavelength of the second excitation light;

[0019] The wavelength of the fluorescence emitted by the second fluorescent molecule after being excited by the first excitation light is different from the wavelength of the second excitation light;

[0020] Step (c): observing the cell fluid with a high-content cell imager, using the first excitation light to excite the second fluorescent molecule to emit fluorescence and screening out candidate cells surrounded by the fluorescence of the second fluorescent molecule, marking them as target candidate cells; then irradiating the target candidate cells with the second excitation light to put the marked first fluorescent molecule into a photoactivated or photoconverted state;

[0021] Step (d): using a flow cytometer to sort the candidate cells in the cell fluid. During the sorting process, the candidate cells treated in step (c) are irradiated with the third excitation light and the target candidate cells emitting the first fluorescence are sorted out, i.e., the cells secreting the target antibody.

[0022] The screening method provided by the present invention can screen cells that secrete antibodies at a high throughput, and the screening principle is as follows:

[0023] Since the target antibody is secretory, the target antibody is secreted outside the cell and distributed around the candidate cells. Therefore, when the first excitation light is used to irradiate the candidate cells, the second fluorescent molecules can be stimulated to emit fluorescence. At this time, the candidate cells that can secrete the target antibody will be surrounded by fluorescence, while the candidate cells that cannot secrete the target antibody will not be surrounded by fluorescence. Based on this phenomenon, the candidate cells that can secrete the antibody can be preliminarily determined; then the second excitation light is used to specifically excite them, so that the first fluorescent molecules marked by them are in a photoactivated or photoconverted state; and then in the screening step using the flow cytometer, when the third excitation light is used for excitation, the first fluorescent molecules in the photoactivated or photoconverted state will emit the first fluorescence, while the fluorescent molecules that have not been excited by the second excitation light will emit the second fluorescence; accordingly, according to the difference between the first fluorescence and the second fluorescence, the candidate cells that can secrete the target antibody and the candidate cells that cannot secrete the target antibody can be distinguished and screened out.

[0024] From the screening principle, it can be seen that for cell screening of secretory antibodies, the screening method provided by the present invention can complete the labeling and sorting of target candidate cells in a high-throughput and automated manner through the labeling of fluorescent molecules in combination with a high-content cell imager and a flow cytometer, thereby providing a sufficient number of cell basis for the subsequent amplification of its antibody sequence and screening of antibodies with affinity, thereby improving the screening efficiency.

[0025] It should be noted that the "different fluorescence" in the aforementioned "the fluorescence emitted by the first fluorescent molecule after being excited by the first excitation light is different from the fluorescence emitted by the second fluorescent molecule after being excited by the first excitation light" means that: the fluorescence wavelengths of the two fluorescent molecules are different, or the second fluorescent molecule emits fluorescence but the first fluorescent molecule does not emit fluorescence. The type of the second fluorescent molecule can be reasonably selected according to the type of the first fluorescent molecule, as long as the fluorescence of the second fluorescent molecule can be distinguished from the fluorescence of the first fluorescent molecule under the excitation of the first excitation light. According to the above content, those skilled in the art can easily understand that the wavelengths of the first excitation light and the second excitation light are different to avoid mutual influence.

[0026] In an optional embodiment, the first fluorescent molecule is selected from photoactivated fluorescent protein and photoconversion fluorescent protein.

[0027] In an optional embodiment, in step (d), when the cell fluid is sorted by a flow cytometer, the second fluorescent molecule is a fluorescent molecule that does not emit fluorescence under the excitation of the third excitation light, or the wavelength of the fluorescence emitted under the excitation of the third excitation light is different depending on whether the cell fluid contains a labeled antibody.

[0028] When the cell fluid is directly sorted, it contains a labeled antibody, and the fluorescence property of the second fluorescent molecule should meet the following condition (a): it does not emit fluorescence under the excitation of the third excitation light, or the wavelength of the fluorescence emitted by it under the excitation of the third excitation light is different from the wavelength of the first fluorescence. Under the premise of meeting this condition, the fluorescence interference caused by the second fluorescent molecule in the sorting can be avoided. When the solution used for sorting contains or does not contain a labeled antibody, the second fluorescent molecule may not meet the above condition (a).

[0029] Whether to use cell fluid directly for sorting can be determined based on the fixation method of the captured antigen.

[0030] For example, when the captured antigen is fixed in a container (e.g., a cell culture dish) by cells expressing the antigen (e.g., adherent cells), in this case, the candidate cells are difficult to separate, so the cell fluid can be digested to form a cell suspension and then directly used for subsequent sorting. In this case, the cell fluid used for sorting contains a labeled antibody. In this case, the second fluorescent molecule needs to meet the above condition (a).

[0031] For another example, when the capture antigen is directly fixed or coated in a container (such as a cell culture dish) through other media (such as microspheres or magnetic beads, etc.), in this case, the candidate cells can be easily separated from the cell fluid by washing. Then, in this case, the candidate cells can be separated separately, and then diluted with a suitable diluent for subsequent analysis steps. In this case, the cell fluid used for sorting does not contain the labeled antibody, and the second fluorescent molecule may not meet the above condition (a).

[0032] In an optional embodiment, the container contains adherent cells that overexpress the capture antigen. The capture antigen is fixed in the container by the adherent cells expressing the antigen. The fixed capture antigen can concentrate the antibodies secreted by the candidate cells around the candidate cells, which is convenient for fluorescence observation.

[0033] In an optional embodiment, after the treatment in step (c), the cell fluid is digested to obtain a cell suspension, and the cell suspension is sorted by flow cytometry.

[0034] In an optional embodiment, the photoactivated fluorescent protein is PA-GFP.

[0035] In an optional embodiment, when the first fluorescent molecule is PA-GFP protein, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 450nm-550nm (the maximum excitation light wavelength is 504nm).

[0036] When the first fluorescent molecule is PA-GFP protein, a high-content cell imaging instrument is used to screen out candidate cells surrounded by the fluorescence of the second fluorescent molecule, and then irradiated with strong purple light, i.e., the second excitation light (390nm-415nm), the green fluorescence generated by this variant is increased by 100 times. Through a flow cytometer, the third excitation light with an excitation light wavelength range of 450nm-550nm (maximum excitation light is 504nm) is used for irradiation, and the wavelength range of the emission light of the candidate cells is 480nm-600nm (maximum emission light is 517nm). At this time, non-candidate cells that have not been irradiated with the second excitation light emit weaker green fluorescence when irradiated with the third excitation light, and the wavelength range of the emission light is 480nm-600nm (maximum emission light is 515nm). The different fluorescence intensities of the emission light can be used to sort out the candidate cells with PA-GFP protein that can secrete the target antibody after light activation.

[0037] In an alternative embodiment, the photoconvertible fluorescent protein is selected from PS-CFP2, PS-CFP, mEosFP, tdEosFP, dEosFP, WtEosFP, Kaede, Dendra2 and KikGR.

[0038] In an optional embodiment, when the first fluorescent molecule is PS-CFP2 protein, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 420nm-520nm (the maximum excitation light wavelength is 490nm);

[0039] When the first fluorescent molecule is PS-CFP2 protein, a high-content cell imager is used to screen out candidate cells surrounded by the fluorescence of the second fluorescent molecule, and then irradiated with strong purple light, i.e., the second excitation light (390nm-415nm), the candidate cells with blue-green fluorescence are photoconverted into green fluorescence. Through the flow cytometer, after excitation by the third excitation light, the wavelength range is 420nm-520nm (the maximum excitation light wavelength is 490nm), and the emission light wavelength range of the candidate cells irradiated by the second excitation light is 450nm-600nm (the maximum emission light wavelength is 511nm). At this time, the candidate cells that have not been irradiated by the second excitation light do not emit fluorescence when irradiated by the third excitation light. Therefore, the candidate cells that secrete the target antibody can be sorted out.

[0040] In an optional embodiment, when the first fluorescent molecule is Kaede protein, the wavelength range of the first excitation light is not within the range of 350nm-400nm, the wavelength of the second excitation light is 350nm-400nm, and the wavelength range of the third excitation light is 500nm-600nm (the maximum excitation light wavelength is 572nm).

[0041] When the first fluorescent molecule is Kaede protein, a high-content cell imager is used to screen out candidate cells surrounded by the fluorescence of the second fluorescent molecule, and then irradiated with strong purple light, i.e., the second excitation light (350nm-400nm), the candidate cells with green fluorescence are photoconverted into red fluorescence. Through the flow cytometer, after excitation by the third excitation light, the wavelength range is 500nm-600nm (the maximum excitation light wavelength is 572nm), and the emission wavelength range of the candidate cells irradiated by the second excitation light is 550nm-650nm (the maximum emission light is 580nm). At this time, the candidate cells not irradiated by the second excitation light do not emit fluorescence when irradiated by the third excitation light. Therefore, the candidate cells that secrete the target antibody can be sorted out.

[0042] In an optional embodiment, the first fluorescent molecule is KikGR protein, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 500nm-600nm (the maximum excitation light wavelength is 583nm).

[0043] When the first fluorescent molecule is kikGR protein, a high-content cell imager is used to screen out candidate cells surrounded by the fluorescence of the second fluorescent molecule, and then irradiated with strong purple light, i.e., the second excitation light (390nm-415nm), the candidate cells with green fluorescence are photoconverted into red fluorescence. Through the flow cytometer, after excitation by the third excitation light, the wavelength range is 500nm-600nm (the maximum excitation light wavelength is 583nm), and the emission light wavelength range of the candidate cells irradiated by the second excitation light is 550nm-650nm (the maximum emission light wavelength is 593nm). At this time, the candidate cells that have not been irradiated by the second excitation light do not emit fluorescence when irradiated by the third excitation light. Therefore, the candidate cells that secrete the target antibody can be sorted out.

[0044] In an alternative embodiment, the candidate cells in step (a) are selected from B lymphocytes, T cells, NK cells, HEK cells, CHO cells, bacteria and yeast.

[0045] The type of candidate cells can be selected as needed, and any cell that is expected to secrete the target antibody can be used as a candidate cell of the present invention. For example, typical secretory antibody-secreting cells include B lymphocytes. In some embodiments, the cells may be spleen cells, bone marrow cells, lymph node cells, etc. from an immunized host animal.

[0046] However, it should be noted that, according to the screening principle of the invention, it can be understood that the method of the present invention can be used not only to screen cells that secrete antibodies, but also to screen cells that secrete any protein. Therefore, the use of the method of the present invention for screening cells that secrete other proteins also falls within the scope of protection of the present invention.

[0047] In an optional embodiment, in step (a), the method of labeling the candidate cells with the first fluorescent molecule is selected from any one of the following methods (I)-(IV):

[0048] (I): introducing a nucleotide encoding the first fluorescent molecule into the candidate cell and allowing the nucleotide to express the first fluorescent molecule in the candidate cell;

[0049] (II): introducing the first fluorescent molecule into the candidate cell by electrotransfection; (III): fusing the first fluorescent molecule with an antibody of a specific marker on the cell membrane surface of the candidate cell, and connecting the first fluorescent molecule to the surface of the candidate cell through the specific binding of the antibody with the specific marker;

[0050] (IV): Labeling lipid substances with the first fluorescent molecules, and then mixing the lipid-labeled first fluorescent molecules with the candidate cells so that the first fluorescent molecules are connected to the surface of the candidate cells.

[0051] It should be noted that the method of labeling the first fluorescent molecule on the candidate cell is not limited to the method shown in (I)-(IV) above. The technicians in this field can easily achieve the labeling of the first fluorescent molecule according to the conventional technology in the field. Using other methods to label the first fluorescent molecule on the candidate cell also falls within the protection scope of the present invention. In addition, the first fluorescent molecule can be labeled on the surface or inside the candidate cell, or on the surface and inside the cell.

[0052] In an optional embodiment, the lipid substance is selected from DSPE-NHS, DSPE-polyethylene glycol (PEG) 2000-NHS, DSPE-PEG3400-NHS, oleyl-PEG2000-NHS, oleyl-PEG4000-NHS and dioleoylphosphatidylethanolamine (DOPE)-PEG2000-NHS.

[0053] In an optional embodiment, in step (c), imaging is performed under a low-power microscope to screen out the target candidate cells; then the microscope is switched to a high-power microscope to irradiate the target candidate cells with the second excitation light.

[0054] In an optional embodiment, in order to avoid the suspension of candidate cells and the dispersion of secreted antibodies, cells expressing captured antigens or beads (such as magnetic beads) connected to captured antigens can also be inoculated in the culture container containing the incubation system. These cells or beads can also express or couple some capture molecules on the surface, such as anti-CD19 antibodies, anti-B lymphocyte antibodies, anti-CD19 scFv and other capture molecules, which can capture candidate cells without letting them be in a suspended state. Alternatively, gelatin can be added to the incubation system to reduce the fluidity of cells and antibodies, which is conducive to detection and observation.

[0055] In an optional embodiment, before performing step (d), the cell fluid obtained in step (c) is digested into a single cell suspension, and the single cell suspension is sorted.

[0056] In an optional embodiment, in step (d), sorting can also be achieved using a micro-control flow chip.

[0057] In another aspect, the present invention provides a method for screening a target antibody, comprising the following steps:

[0058] Obtaining cells secreting the target antibody using any of the methods described above;

[0059] The nucleotide sequence encoding the target antibody is obtained from the obtained cells secreting the target antibody. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0061] Figure 1 : The heavy chain variable region sequence and light chain variable region sequence of the antibody were obtained by PCR, both of which were about 400 bp in size.

[0062] Figure 2 : The 5' untranslated region required to constitute the full-length antibody sequence was obtained by PCR, which was about 400 bp in size, the heavy chain antibody constant region and 3' untranslated region, which were about 1200 bp in size, and the light chain antibody constant region and 3' untranslated region, which were about 400 bp in size.

[0063] Figure 3 :The variable regions of the light and heavy chains of the antibody are reconstructed into complete full-length antibody sequences by overlap PCR. The size of the heavy chain full-length antibody sequence is about 1900 bp, and the size of the light chain full-length antibody sequence is about 1000 bp.

[0064] Figure 4 : Antibody affinity detection using high content, showing that the captured antigen is surrounded by labeled antibodies labeled with a second fluorescent molecule.

[0065] Figure 5 : B lymphocytes secreting specific anti-PDL1 antibodies are surrounded by a halo. DETAILED DESCRIPTION

[0066] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0067] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0068] Example 1

[0069] This example takes anti-PDL1 antibodies and B lymphocytes as examples to illustrate the method for screening B lymphocytes secreting anti-PDL1 antibodies provided in this example, which includes the following:

[0070] 1. Immunize mice using PDL1 protein as an antigen. Refer to conventional methods in the art.

[0071] 2. Enrichment of B lymphocytes

[0072] 1) The spleen of the mouse was removed and placed on a 40 μm filter. The spleen was crushed through the filter to obtain single spleen cells, which were placed in 50 ml of pre-cooled serum-free 1640 culture medium.

[0073] 2) Centrifuge at 4°C, 500g for 5 min.

[0074] 3) Discard the supernatant, resuspend the cells in 10 ml 1× lysis buffer (BD bioscience, cat: 555899), and incubate at room temperature in the dark for 5 min.

[0075] 4) Add 40 ml of serum-free 1640 medium and centrifuge at 4°C, 500 g for 5 min.

[0076] 5) Discard the supernatant, resuspend the cell pellet in 10 ml MACS Buffer (MACS Buffer: miltenyi biotecorder no.130-091-221), blow evenly, stain with trypan blue, and count.

[0077] 6) Take 5×10 7 Centrifuge cells at 4°C, 500g for 5 min and discard the supernatant.

[0078] 7) Add 175 μl MACS buffer, 25 μl FcR Blocking Reagent, and 50 μl Biotin-Antibody Cocktail (Pan B Cell Isolation Kit II, mouse (Order no: 130-104-443)), mix well, and incubate at 4°C for 5 min.

[0079] 8) Add 150 μl MACS buffer and 100 μl Anti-Biotin MicroBeads to the cell suspension, mix well, and incubate at 4°C for 10 min.

[0080] 9) Equilibrate the LS column with 3 ml of Buffer.

[0081] 10) The cell suspension was passed through a column (500 μl) and the filtrate was collected.

[0082] 11) Add another 3 ml of Buffer to the LS column and collect the filtrate into a centrifuge tube.

[0083] 12) The obtained filtrate 3.5 ml is the candidate B lymphocytes

[0084] 3. Enrichment of B lymphocytes before packaging of lentivirus

[0085] 1) Take out densely grown 293T cells with a density of about 80%-90%, and replace them with fresh culture medium (DMEM+10% FBS), 10 ml / 10 cm cell culture dish.

[0086] 2) Take two 2 ml centrifuge tubes, add 625 μl of DMEM medium and 18.75 μl of Lipofectamine3000 to tube 1. Add 625 μl of DMEM medium, 7.5 ug of psPAX2 plasmid, 2.5 ug of PMD2G plasmid, 10 ug of PLVX-Kaede-IRES-PURO plasmid, and 25 μl of P3000 to tube 2.

[0087] 3) Transfer the solution in tube 1 to tube 2, mix the solution in the tube with an oscillator, and let it stand for 5 minutes.

[0088] 4) Take out the 293T cells, gently transfer the mixture into the cells, and return them to the incubator.

[0089] 5) After 48 hours, collect the lentiviral supernatant for the first time and add 10 ml / dish of fresh culture medium to the cells.

[0090] 6) After 72 hours, collect the lentivirus for the second time, centrifuge the virus supernatant at 4°C, 60,000g, for 2 hours, and discard the supernatant. Resuspend the precipitate with an appropriate amount of PBS to obtain the concentrated virus with a titer of 10 7 u / ml.

[0091] 4. Virus infection of B lymphocytes to obtain B lymphocytes expressing Kaede protein (first fluorescent molecule)

[0092] 1) Infect isolated B lymphocytes at MOI=50 (any value between 10 and 100, preferably 50). After 6 hours (any value between 30 minutes and 48 hours, preferably 6 hours) of transfection, centrifuge the cell suspension at 500 g for 5 minutes, discard the supernatant, and obtain B lymphocytes expressing Kaede protein.

[0093] 5. Plate the transfected B lymphocytes

[0094] 1) One day before transfection, CHO-K1 cells overexpressing PDL1 (capture antigen) were seeded into cell culture dishes.

[0095] 2) The transfected B lymphocytes were plated in a dish. The number of cells plated was preferably 2×10 6 (2×10 4 -2×10 7After 6-48h of culture, gently aspirate the culture medium, add Goat pAb to Ms IgG (AleaxFlour 647, abcam, cat: ab150115) staining solution (containing the secondary antibody labeled with the second fluorescent molecule Aleax Flour 647) prepared with fresh culture medium, with a working concentration of 0.2μg / ml, avoid disturbing B cells, incubate at 37℃, 5% CO2 for 30min, gently aspirate the staining solution, replace with fresh culture medium, and avoid disturbing B cells during the liquid replacement process.

[0096] 6 Place the cell culture dish into the high-content cell imaging instrument for detection

[0097] 1) Using a high-content cell imager, imaging was performed under a 5x microscope, using the first excitation light (550nm-700nm) for excitation, and the Aleax Flour 647 emission light wavelength range was 620nm-750nm. It was observed that the CHO-K1 cells overexpressing PDL1 around the B lymphocytes secreting specific anti-PDL1 antibodies were surrounded by a red halo (see Figure 5 ), and then switch to a 60x high-power microscope to photoactivate the B lymphocytes. The wavelength of the second excitation light (second excitation light) is 365nm (350nm~400nm is acceptable), and the exposure time is 500ms (50ms-5000ms is acceptable), which promotes photoconversion without emitting light.

[0098] 7. Flow cytometry sorting of single B lymphocytes secreting specific antibodies

[0099] 1) The cells in step 6 are digested into a single cell suspension, sorted using a flow cytometer, excited using 500nm-600nm excitation light (maximum excitation wavelength 572nm), and emission light is obtained in the range of 550nm to 650nm (after step 6, the target B cells with halos (capable of secreting target antibodies) are photoconverted and emit red emission light with a wavelength of 580nm, and the B lymphocytes that have not been photoconverted in step 6 (cannot secrete target antibodies) do not have fluorescence), and the photoconverted B lymphocytes with red emission light (i.e., B lymphocytes that secrete anti-PDL1 antibodies) are sorted into a PCR tube containing cell lysate.

[0100] Example 2

[0101] This example takes the B lymphocytes secreting anti-PDL1 antibodies obtained by screening in Example 1 as an example to illustrate the method for screening anti-PDL1 antibodies, which includes the following steps:

[0102] 1 Reverse the first strand of cDNA and amplify the full-length cDNA by 5'RACE method.

[0103] 1) First-strand cDNA synthesis ( RACE 5' / 3'Kit, Takara, cat: 634858)

[0104] A: Prepare the reaction system

[0105] Mix1:

[0106]

[0107]

[0108] Mix gently using a pipette, centrifuge briefly and bring to room temperature.

[0109] Mix2:

[0110] Components volume RNA 6μl Cap Primer 1μl <![CDATA[Deionized H2O]]> 4μl Total 11μl

[0111] Cap Primer: AGCAGTGGTATCAACGCAGAGTACrGrGG; mix gently using a pipette and centrifuge briefly.

[0112] Mix 2 was reacted under the following conditions.

[0113] temperature time 72℃ 3min 42℃ 2min Centrifugation at 14000g 10s

[0114] B: Prepare the reaction system:

[0115] Mix3:

[0116] Components volume Mix1 5.5μl RNase Inhibition 0.5μl SMARTScribe Reverse Transcriptase 2μl Total 8μl

[0117] Mix gently using a pipette and centrifuge briefly.

[0118] C: First-strand cDNA synthesis

[0119] Mix4:

[0120]

[0121]

[0122] oligo-dT primer:

[0123] AGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN. Mix gently using a pipette and centrifuge briefly.

[0124] Reaction conditions:

[0125] temperature time 42℃ 90min 70℃ 10min

[0126] D: Full-length cDNA amplification

[0127] Mix5:

[0128] Components volume <![CDATA[Deionized H2O]]> 15.5μl 2X SeqAmp Buffer 25μl SeqAmp DNA Polymerase 1μl Total 41.5μl

[0129] Mix gently using a pipette and centrifuge briefly.

[0130] Mix6:

[0131] Components volume Mix4 2.5μl ISPCR primer 5μl oligo-dT primer 1μl Mix 5 41.5μl Total 50μl

[0132] oligo-dT primer:

[0133] AGCAGTGGTATCAACGCAGAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTVN.

[0134] ISPCR primer:AAGCAGTGGTATCAACGCAGAGT.

[0135] PCR conditions:

[0136]

[0137]

[0138] 2 Obtain the heavy chain variable region sequence and light chain variable region sequence of the antibody by PCR.

[0139] Prepare PCR reaction system:

[0140]

[0141] PCR conditions:

[0142]

[0143] The antibody heavy chain variable region forward primer is FVH_mix (equal volumes of nine 10 μM primers FVH_I to IX are taken and mixed).

[0144] The antibody heavy chain variable region reward primer is RVH_mix (four 10μM primers RVH_I~IV are extracted and mixed in equal volumes). The antibody heavy chain variable region forward primer and reward primer are shown in the following table:

[0145]

[0146]

[0147] The forward primer of the antibody light chain variable region is FVK_mix (equal volumes of nine 10 μM primers FVKFK_I to IX are taken and combined).

[0148] The reward primer for the variable region of the antibody light chain is RVK_mix (three primers RVK_I to III of 10 μM are extracted in equal volumes and mixed).

[0149] The forward primer and reward primer of the antibody light chain variable region are shown in the following table:

[0150]

[0151] The PCR results are as follows Figure 1 shown.

[0152] 3. The variable regions of the antibody's light and heavy chains were reconstructed into complete full-length antibody sequences through overlap PCR and expressed in vitro without cells.

[0153] 1) Obtain the template fragments used for overlap PCR (5'UTR, IgG1Fc-3'UTR, IgKc-3'UTR) by PCR.

[0154] The PCR amplification system for 5'UTR fragment is as follows:

[0155] System (50μl) 5X Q5 reaction buffer 10μl 10nM dNTP 1μl Pd2p_up-F (20μM) 1.25μl (final concentration 0.5μM) TEV-R (20 μM) 1.25μl (final concentration 0.5μM) Plasmid pD2P-1.06 1μl GC enhancer 10μl Q5-high-fidelity DNA polymerase 0.5μl Nuclease-Free Water 25μl

[0156] Pd2p_up-F: ATCGGTGATGTCGGCGATATAG;

[0157] TEV-R: TCCCTGGAAATATAAGTTCTCGCC.

[0158] PCR conditions:

[0159]

[0160] The PCR amplification system for IgG1Fc-3'UTR fragment is as follows:

[0161]

[0162]

[0163] PCR conditions:

[0164]

[0165] IgG1Fc_F2: GCCAAAACCACACCTCCT;

[0166] Pd2p-R: AGCAGCCGGATCGTCGAGTTCG.

[0167] The PCR amplification system of IgKc-3'UTR fragment is as follows:

[0168] Components System (50μl) 5X Q5 reaction buffer 10μl 10nM dNTP 1μl IgKc-F2 (20 μM) 1.25μl (final concentration 0.5μM) Pd2p-R (20μM) 1.25μl (final concentration 0.5μM) Plasmid PGM-IgKc-3'UTR 1μl GC enhancer 10μl Q5-high-fidelity DNA polymerase 0.5μl Nuclease-Free Water 25μl

[0169] IgKc-F2: AGAGCTGACGCCGCTCCT;

[0170] Pd2p-R: AGCAGCCGGATCGTCGAGTTCG.

[0171] PCR conditions:

[0172]

[0173]

[0174] PCR results are as follows Figure 2 shown.

[0175] 2) The light and heavy chain variable regions of the antibody were reconstructed into complete full-length antibody sequences by overlap PCR.

[0176]

[0177] pD2P_F:ATCGAGATCTCGCGAAATTAATACGA;

[0178] pD2P_R:AGCAGCCGGATCGTCGAGTTCG.

[0179] Overlap PCR conditions:

[0180]

[0181] PCR results are as follows Figure 3 shown.

[0182] 3) In vitro cell-free expression

[0183] Add 1 μl of each of the complete antibody sequences of the light and heavy chains of the antibody obtained by overlap PCR to 60 μl of ProteinFactory Rxn (protein factory 1.0) reaction system. Let stand at 20-30°C for 3-20 hours to complete protein expression and obtain anti-PDL1 antibodies.

[0184] 4. After obtaining the expressed antibody, perform antibody affinity screening

[0185] 1) One day in advance, take CHO-K1 cells overexpressing PDL1 (10,000 cells per well) and CHO-K1 cells overexpressing GFP (2,000 cells per well) and mix them in F-12 medium, 100 μl / well, and seed a 96-well plate. Incubate overnight at 37°C, 5% CO2.

[0186] 2) Aspirate the culture medium in the culture plate and add 40 μl of antibody protein to each well, and incubate at 37°C, 5% CO2 for 30 min.

[0187] 3) Aspirate the protein, add Goat pAb to Ms IgG (Aleax Flour 647, cat: ab150115, abcam), working concentration 0.2 μg / ml and Hoechest 33342, working concentration 0.2 μg / ml to F-12 medium, 50 μl per well, and incubate at 37°C, 5% CO2 for 30 min.

[0188] 4) Aspirate the culture medium and add 50 μl of F-12 culture medium.

[0189] 5) High-content imaging and analysis of average fluorescence values ​​(see Figure 4 ). The analysis method is as follows:

[0190] a) By using 350 nm excitation light, find the cell nuclei stained by Hoechest 33342 and adjust the fluorescence value to find the total cells.

[0191] b) Among the cells output in a), cells with green fluorescence were found by using 488 nm excitation light, and the fluorescence value was adjusted and output as CHO-K1-GFP.

[0192] c) The total number of cells was subtracted from the CHO-K1-GFP in b), and the remaining cells were CHO-K1-PDL1.

[0193] d) By using 647 nm excitation light, the red fluorescence value on the cell membrane was detected, and the average red fluorescence value on the CHO-K1-GFP membrane and the average red fluorescence value on the CHO-K1-PDL1 membrane were calculated.

[0194] e) The antibody affinity screening is performed by calculating the ratio of the average red fluorescence on the CHO-K1-PDL1 membrane to the average red fluorescence on the CHO-K1-GFP membrane. An antibody with a higher ratio is selected, that is, an anti-PDL1 antibody with high affinity is obtained.

[0195] Example 3

[0196] The method for screening B lymphocytes secreting anti-PDL1 antibodies provided in this example is basically the same as that in Example 1, except for the step of plating the transfected B lymphocytes. The operation method of this example is as follows:

[0197] 1) One day before transfection, dilute Poly-D-Lysine solution (gibco, REF: A3890401) to a working concentration of 50 ug / ml using sterile DPBS. In other embodiments, semi-solid culture medium or gelatin may also be used in this step.

[0198] 2) Add the diluent to a six-well plate (this step can increase cell adhesion), adding 2 ml to each well.

[0199] 3) Incubate at room temperature for 1 hour.

[0200] 4) Discard the diluent and wash the six-well plate three times with sterile water to ensure that the residual Poly-D-Lysine solution is removed.

[0201] 5) Place the six-well plate with the lid open in a biosafety cabinet.

[0202] 6) After the six-well plate is completely dry, CHO-K1 cells overexpressing PDL1 are plated in the six-well plate.

[0203] 7) Spread the transfected B lymphocytes into a dish. After culturing for 6-48 hours, gently aspirate the culture medium, add Goat pAb to Ms IgG (Aleax Flour 647, abcam, cat: ab150115) staining solution prepared with fresh culture medium, with a working concentration of 0.2 μg / ml, avoid disturbing the B cells, incubate at 37°C, 5% CO2 for 30 minutes, gently aspirate the staining solution, replace with fresh culture medium, and avoid disturbing the B cells during the liquid replacement process.

[0204] The remaining steps are the same as in Example 1.

[0205] Example 4

[0206] The method for screening B lymphocytes secreting anti-PDL1 antibodies provided in this embodiment is basically the same as that in Example 1, except that: the first fluorescent molecule is PA-GFP protein; in addition, in this embodiment, in the high-content cell imaging step: using strong purple light (390-415nm) for irradiation, the green fluorescence (wavelength range of 480nm-600nm) produced by the candidate cells is increased by 100 times; when sorting by flow cytometry, the excitation light wavelength range is 450nm-550nm (maximum excitation light is 504nm), and the emission light wavelength range is 480nm-600nm (maximum emission light is 517nm), so that the light-activated labeled B lymphocytes with PA-GFP protein that can secrete target antibodies can be sorted out.

[0207] Example 5

[0208] The method for screening B lymphocytes secreting anti-PDL1 antibodies provided in this embodiment is basically the same as that in Example 1, and the first fluorescent molecule is Kaede protein; in the high-content cell imaging step: using strong purple light (350-400nm) to irradiate, candidate B lymphocytes with green fluorescence (wavelength range of 500nm-600nm) are photoconverted into red fluorescence (wavelength range of 550nm-650nm); when sorting by flow cytometer, the excitation light wavelength range is 500nm-600nm (maximum excitation light wavelength is 572nm), and the emission light wavelength range is 550nm-650nm (maximum emission light is 580nm), so that the photoconverted B lymphocytes marked with Kaede protein that can secrete antibodies can be sorted out.

[0209] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for screening cells that secrete a target antibody, characterized in that: It includes the following steps: Step (a): labeling the candidate cells with a first fluorescent molecule; Step (b): adding the candidate cells labeled with the first fluorescent molecule and the labeled antibody against the target antibody to a container fixed with a capture antigen, mixing and incubating to obtain a cell fluid; wherein the capture antigen can specifically bind to the target antibody; and the labeled antibody is labeled with a second fluorescent molecule; The first fluorescent molecule has the following properties: the fluorescence emitted by the first fluorescent molecule after being excited by the first excitation light is different from the fluorescence emitted by the second fluorescent molecule after being excited by the first excitation light; the first fluorescent molecule is in a photoactivated or photoconverted state after being excited by the second excitation light, and emits the first fluorescence after being excited by the third excitation light while in the photoactivated or photoconverted state; and the first fluorescent molecule emits the second fluorescence after being directly excited by the third excitation light without being excited by the second excitation light; the wavelength of the first fluorescence is different from the wavelength of the second fluorescence, or the wavelength of the first fluorescence is the same as the wavelength of the second fluorescence but the fluorescence intensity is different; wherein the wavelength of the first excitation light is different from the wavelength of the second excitation light; the wavelength of the second excitation light is different from the wavelength of the third excitation light; The wavelength of the fluorescence emitted by the second fluorescent molecule after being excited by the first excitation light is different from the wavelength of the second excitation light; Step (c): observing the cell fluid with a high-content cell imager, using the first excitation light to excite the second fluorescent molecule to emit fluorescence and screening out candidate cells surrounded by the fluorescence, marking them as target candidate cells; then irradiating the target candidate cells with the second excitation light to put the marked first fluorescent molecule into a photoactivated or photoconverted state; Step (d): using a flow cytometer to sort the candidate cells in the cell fluid. During the sorting process, the candidate cells treated in step (c) are irradiated with the third excitation light and the target candidate cells emitting the first fluorescence are sorted out, i.e., the cells secreting the target antibody.

2. The method according to claim 1, characterized in that: The first fluorescent molecule is selected from any one of a photoactivated fluorescent protein and a photoconvertible fluorescent protein.

3. The method according to claim 2, characterized in that In step (d), when the cell fluid is sorted by flow cytometry, the second fluorescent molecule is a fluorescent molecule that does not emit fluorescence under the excitation of the third excitation light, or is a fluorescent molecule that emits fluorescence with a wavelength different from the wavelength of the first fluorescence under the excitation of the third excitation light.

4. The method according to claim 3, characterized in that The photoactivated fluorescent protein is PA-GFP; Preferably, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength range of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 450nm-550nm.

5. The method according to claim 3, characterized in that: The photoconversion fluorescent protein is selected from any one of PS-CFP2, PS-CFP, mEosFP, tdEosFP, dEosFP, WtEosFP, Kaede, Dendra2 and KikGR.

6. The method according to claim 5, characterized in that The first fluorescent molecule is PS-CFP2 protein, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 420nm-520nm; Alternatively, the first fluorescent molecule is Kaede protein, the wavelength range of the first excitation light is not within the range of 350nm-400nm, the wavelength of the second excitation light is 350nm-400nmnm, and the wavelength range of the third excitation light is 500nm-600nm; Alternatively, the first fluorescent molecule is KikGR protein, the wavelength range of the first excitation light is not within the range of 390nm-415nm, the wavelength of the second excitation light is 390nm-415nm, and the wavelength range of the third excitation light is 500nm-600nm.

7. The method according to any one of claims 1 to 6, characterized in that: The candidate cells in step (a) are selected from the group consisting of B lymphocytes, T cells, NK cells, HEK cells, CHO cells, bacteria and yeast.

8. The method according to any one of claims 2 to 6, characterized in that: In step (a), the method of labeling the candidate cells with the first fluorescent molecule is selected from any one of the following methods (I) to (IV): (I): introducing a nucleotide encoding the first fluorescent molecule into the candidate cell and allowing the nucleotide to express the first fluorescent molecule in the candidate cell; (II): introducing the first fluorescent molecule into the candidate cell by electrofection; (III): fusing the first fluorescent molecule with an antibody for a specific marker on the cell membrane surface of the candidate cell, and connecting the first fluorescent molecule to the surface of the candidate cell through the specific binding of the antibody to the specific marker; (IV): Labeling lipid substances with the first fluorescent molecules, and then mixing the lipid-labeled first fluorescent molecules with the candidate cells so that the first fluorescent molecules are connected to the surface of the candidate cells.

9. The method according to claim 8, characterized in that The lipid substance is selected from DSPE-NHS, DSPE-PEG2000-NHS, DSPE-PEG3400-NHS, oleyl-PEG2000-NHS, oleyl-PEG4000-NHS and DOPE-PEG2000-NHS.

10. A method for screening a target antibody, characterized in that: It includes the following steps: Obtaining cells secreting a target antibody using the method of any one of claims 1 to 9; The nucleotide sequence encoding the target antibody is obtained from the obtained cells secreting the target antibody.

Citation Information

Patent Citations

  • Devices and methods for cellular secretion analysis

    CN109154017A

  • Method for efficiently separating single antigen-specific B lymphocyte from spleen cells

    CN110016462A

  • Monoclonal antibody secretory cell screening method based on fluorescence sensor

    CN111398590A

  • Method for selecting antibody expressing cells

    US20040219611A1

  • Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens

    US20140287952A1